Pyxis Oncology, Inc.
PYXS
$3.38
-$0.51-13.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 11.04M | -- | 2.82M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 11.04M | -- | 2.82M |
| Cost of Revenue | -- | -- | 2.39M | -- | -- |
| Gross Profit | -- | -- | 8.65M | -- | 2.82M |
| SG&A Expenses | 9.54M | 3.75M | 4.54M | 4.97M | 4.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.60M | 23.73M | 28.64M | 22.78M | 21.89M |
| Operating Income | -25.60M | -23.73M | -17.60M | -22.78M | -19.07M |
| Income Before Tax | -25.35M | -23.27M | -17.00M | -22.00M | -18.07M |
| Income Tax Expenses | -- | -- | 1.10M | -- | 283.00K |
| Earnings from Continuing Operations | -25.35M | -23.27M | -18.11M | -22.00M | -18.35M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.35M | -23.27M | -18.11M | -22.00M | -18.35M |
| EBIT | -25.60M | -23.73M | -17.60M | -22.78M | -19.07M |
| EBITDA | -25.30M | -23.27M | -14.71M | -22.25M | -18.53M |
| EPS Basic | -0.40 | -0.37 | -0.29 | -0.35 | -0.30 |
| Normalized Basic EPS | -0.25 | -0.23 | -0.17 | -0.22 | -0.18 |
| EPS Diluted | -0.40 | -0.37 | -0.29 | -0.35 | -0.30 |
| Normalized Diluted EPS | -0.25 | -0.23 | -0.17 | -0.22 | -0.18 |
| Average Basic Shares Outstanding | 63.99M | 63.47M | 63.03M | 62.56M | 61.92M |
| Average Diluted Shares Outstanding | 63.99M | 63.47M | 63.03M | 62.56M | 61.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |